Your browser doesn't support javascript.
loading
Comparison of plasma aldosterone measured by chemiluminescence immunoassay and liquid chromatography-tandem mass spectrometry in screening test for primary aldosteronism.
Chen, Wenzhan; Lai, Fenghua; Huang, Xiaoyu; Yu, Shuang; Chen, Nan; Xu, Changliu; Wang, Chenxue; Liang, Shuhui; Li, Yanbing; Xiao, Haipeng; Cao, Xiaopei.
Afiliação
  • Chen W; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Lai F; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Huang X; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Yu S; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Chen N; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Xu C; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Wang C; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Liang S; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Li Y; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Xiao H; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Cao X; Department of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Pract Lab Med ; 39: e00361, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38318433
ABSTRACT

Background:

Whether chemiluminescence immunoassay (CLIA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for plasma aldosterone concentration (PAC) measurement can be used interchangeably in primary aldosteronism (PA) screening is still controversial. The purpose of this study was to compare CLIA to LC-MS/MS for PAC measurement in PA screening.

Methods:

All participants underwent aldosterone-to-renin ratio (ARR) testing. PA was diagnosed by captopril challenge test or saline infusion test. PAC in screening test was measured with CLIA and LC-MS/MS. Plasma direct renin concentration in screening and confirmatory test was measured with CLIA. The concordance between CLIA and LC-MS/MS for PAC measurement in PA screening was analyzed.

Results:

Twenty-one healthy volunteers, 61 patients with essential hypertension (EH) and 43 PA patients were enrolled. Median PAC by CLIA was 84.7 % higher than that by LC-MS/MS in screening test (P < 0.001). A positive correlation of PAC was observed between the two assays (Pearson r coefficient 0.770, P < 0.001). When ARR was used in differentiating PA from EH, there was no difference in the area under the receiver operating characteristic curve between CLIA and LC-MS/MS for PAC measurement (0.968 vs 0.950, P = 0.249).

Conclusion:

CLIA and LC-MS/MS for PAC measurement exhibited high and comparable efficacy in PA screening. CLIA is a reliable and feasible alternative in PA screening test.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article